The World Health Organization (WHO) announced today that it has approved an emergency vaccine for Covid-19, Convidecia, of Chinese laboratories at CanSino Biologics as Beijing struggles to contain a pandemic flare-up.
The vaccine, which is based on a modified human adenovirus, is given in a single dose and is recommended by the WHO for all age groups from the age of 18, the statement said.
The vaccine is 64% effective for the symptomatic form of Covid-19 and 92% against severe forms of the disease.
It is the ninth vaccine against Covid or a variant of the vaccine that receives this valuable WHO approval, which is a seal of quality, efficacy and safety. An important indication for the health authorities of some countries that do not have the means to make a serious evaluation of the preparation themselves.
This approval also allows the international Covax system to use Convidecia on a case-by-case basis for vaccination, especially in poor countries.
China has been called upon in recent months to face an unprecedented pandemic resurgence in the country, where the first cases of Covid-19 were detected in late 2019.
The Omicron variant and its sub-variants are so contagious that they bypass the very strict sanitary measures imposed by the Chinese authorities.
However, under the leadership of President Xi Jinping, the country continues to implement the zero Covid strategy, not hesitating to impose strict quarantine on big cities like Shanghai for example, for several weeks.
The WHO, for its part, says Covid’s “zero tolerance” policy towards Omicron is “unsustainable”.
Source: ΑΠΕ-ΜΠΕ
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.